76-90 of 825
How Muscarinic Therapies Are Redefining Schizophrenia Care
NeuroFrontiersHow Muscarinic Therapies Are Redefining Schizophrenia Care
Michael Halassa, MD, PhD
Parkinson’s Research in Focus: Translating Science Into Clinical Progress
NeuroFrontiersParkinson’s Research in Focus: Translating Science Into Clinical Progress
Jerome Lisk, MD, MBA, M.S., FAAN
Michael Salvatore, PhD
Vicki Nejtek-Salvatore, PhD
Identifying and Managing Violence Risk in Schizophrenia Care
On the Frontlines of SchizophreniaIdentifying and Managing Violence Risk in Schizophrenia Care
Alexandria May, PharmD, BCPS
Ragy R. Girgis, MD, MS
Digital Danger: Understanding AI Psychosis in Schizophrenia
On the Frontlines of SchizophreniaDigital Danger: Understanding AI Psychosis in Schizophrenia
Alexandria May, PharmD, BCPS
Ragy R. Girgis, MD, MS
Cracking the Migraine Code: How AI May Transform Diagnosis and Treatment
On the Frontlines of MigraineCracking the Migraine Code: How AI May Transform Diagnosis and Treatment
Ashley Baker, MSN, PMHNP
Chia-Chun Chiang, MD
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Project Oncology®Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Alexandria May, PharmD, BCPS
Nicholas Whipple, MD, MPH
- advertisement
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Project Oncology®Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Alexandria May, PharmD, BCPS
Daniel Landi, MD
Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
On the Frontlines of SchizophreniaNegative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
Brian P. McDonough, MD, FAAFP
Ahmed Makhlouf, MD
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups
Hamid Abuwarda, PhD, BS
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
Sharon Sha, MD, MS
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Alexandria May, PharmD, BCPS
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
NeuroFrontiersEvaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
- advertisement
Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
NeuroFrontiersIndividualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
Aducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
NeuroFrontiersAducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
Ryan Quigley
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiersOptimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
